Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
Studies suggest that the incidence of coinfections in patients with the coronavirus disease 2019 (COVID-19) is low, but a large number of patients receive antimicrobials during hospitalisation. This may fuel a rise in antimicrobial resistance (AMR). We conducted a multicentre point-prevalence survey...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/11/2/176 |
| _version_ | 1797483381414428672 |
|---|---|
| author | Lea Papst Roberto Luzzati Biljana Carević Carlo Tascini Nina Gorišek Miksić Vera Vlahović Palčevski Zorana M. Djordjevic Omar Simonetti Emanuela Sozio Milica Lukić Goran Stevanović Davor Petek Bojana Beović |
| author_facet | Lea Papst Roberto Luzzati Biljana Carević Carlo Tascini Nina Gorišek Miksić Vera Vlahović Palčevski Zorana M. Djordjevic Omar Simonetti Emanuela Sozio Milica Lukić Goran Stevanović Davor Petek Bojana Beović |
| author_sort | Lea Papst |
| collection | DOAJ |
| description | Studies suggest that the incidence of coinfections in patients with the coronavirus disease 2019 (COVID-19) is low, but a large number of patients receive antimicrobials during hospitalisation. This may fuel a rise in antimicrobial resistance (AMR). We conducted a multicentre point-prevalence survey in seven tertiary university hospitals (in medical wards and intensive care units) in Croatia, Italy, Serbia and Slovenia. Of 988 COVID-19 patients, 521 were receiving antibiotics and/or antifungals (52.7%; range across hospitals: 32.9–85.6%) on the day of the study. Differences between hospitals were statistically significant (χ<sup>2</sup> (6, <i>N</i> = 988) = 192.57, <i>p</i> < 0.001). The majority of patients received antibiotics and/or antifungals within 48 h of admission (323/521, 62%; range across hospitals: 17.4–100%), their most common use was empirical (79.4% of prescriptions), and pneumonia was the main indication for starting the treatment (three-quarters of prescriptions). The majority of antibiotics prescribed (69.9%) belonged to the “Watch” group of the World Health Organization AWaRe classification. The pattern of antimicrobial use differed across hospitals. The data show that early empiric use of broad-spectrum antibiotics is common in COVID-19 patients, and that the pattern of antimicrobial use varies across hospitals. Judicious use of antimicrobials is warranted to prevent an increase in AMR. |
| first_indexed | 2024-03-09T22:46:08Z |
| format | Article |
| id | doaj.art-18a44883cff64718876b7d7f4fd1a270 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T22:46:08Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-18a44883cff64718876b7d7f4fd1a2702023-11-23T18:27:41ZengMDPI AGAntibiotics2079-63822022-01-0111217610.3390/antibiotics11020176Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence StudyLea Papst0Roberto Luzzati1Biljana Carević2Carlo Tascini3Nina Gorišek Miksić4Vera Vlahović Palčevski5Zorana M. Djordjevic6Omar Simonetti7Emanuela Sozio8Milica Lukić9Goran Stevanović10Davor Petek11Bojana Beović12Department of Infectious Diseases, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, SloveniaDepartment of Infectious Diseases, Azienda Sanitaria Universitaria Giuliano Isontina, Via Giacomo Puccini 50, 34148 Trieste, ItalyDepartment of Hospital Epidemiology, University Clinical Centre of Serbia, Pasterova 2, 11000 Belgrade, SerbiaInfectious Diseases Clinic, Azienda Sanitaria Universitaria Friuli Centrale, Via Pozzuolo 33, 33100 Udine, ItalyDepartment of Infectious Diseases, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, SloveniaUnit of Clinical Pharmacology, Clinical Hospital Center Rijeka, Krešimirova ulica 42, 51000 Rijeka, CroatiaDepartment of Hospital Infections Control, University Clinical Centre Kragujevac, Zmaj Jovina 30, 34000 Kragujevac, SerbiaDepartment of Infectious Diseases, Azienda Sanitaria Universitaria Giuliano Isontina, Via Giacomo Puccini 50, 34148 Trieste, ItalyInfectious Diseases Clinic, Azienda Sanitaria Universitaria Friuli Centrale, Via Pozzuolo 33, 33100 Udine, ItalyDepartment of Infectious Diseases, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, SloveniaDepartment of Hospital Epidemiology, University Clinical Centre of Serbia, Pasterova 2, 11000 Belgrade, SerbiaDepartment of Infectious Diseases, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, SloveniaDepartment of Infectious Diseases, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, SloveniaStudies suggest that the incidence of coinfections in patients with the coronavirus disease 2019 (COVID-19) is low, but a large number of patients receive antimicrobials during hospitalisation. This may fuel a rise in antimicrobial resistance (AMR). We conducted a multicentre point-prevalence survey in seven tertiary university hospitals (in medical wards and intensive care units) in Croatia, Italy, Serbia and Slovenia. Of 988 COVID-19 patients, 521 were receiving antibiotics and/or antifungals (52.7%; range across hospitals: 32.9–85.6%) on the day of the study. Differences between hospitals were statistically significant (χ<sup>2</sup> (6, <i>N</i> = 988) = 192.57, <i>p</i> < 0.001). The majority of patients received antibiotics and/or antifungals within 48 h of admission (323/521, 62%; range across hospitals: 17.4–100%), their most common use was empirical (79.4% of prescriptions), and pneumonia was the main indication for starting the treatment (three-quarters of prescriptions). The majority of antibiotics prescribed (69.9%) belonged to the “Watch” group of the World Health Organization AWaRe classification. The pattern of antimicrobial use differed across hospitals. The data show that early empiric use of broad-spectrum antibiotics is common in COVID-19 patients, and that the pattern of antimicrobial use varies across hospitals. Judicious use of antimicrobials is warranted to prevent an increase in AMR.https://www.mdpi.com/2079-6382/11/2/176COVID-19antimicrobial usemulticentrepoint-prevalence study |
| spellingShingle | Lea Papst Roberto Luzzati Biljana Carević Carlo Tascini Nina Gorišek Miksić Vera Vlahović Palčevski Zorana M. Djordjevic Omar Simonetti Emanuela Sozio Milica Lukić Goran Stevanović Davor Petek Bojana Beović Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study Antibiotics COVID-19 antimicrobial use multicentre point-prevalence study |
| title | Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study |
| title_full | Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study |
| title_fullStr | Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study |
| title_full_unstemmed | Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study |
| title_short | Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study |
| title_sort | antimicrobial use in hospitalised patients with covid 19 an international multicentre point prevalence study |
| topic | COVID-19 antimicrobial use multicentre point-prevalence study |
| url | https://www.mdpi.com/2079-6382/11/2/176 |
| work_keys_str_mv | AT leapapst antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT robertoluzzati antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT biljanacarevic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT carlotascini antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT ninagorisekmiksic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT veravlahovicpalcevski antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT zoranamdjordjevic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT omarsimonetti antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT emanuelasozio antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT milicalukic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT goranstevanovic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT davorpetek antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy AT bojanabeovic antimicrobialuseinhospitalisedpatientswithcovid19aninternationalmulticentrepointprevalencestudy |